Clinical and immunological profile of systemic lupus erythematosis with evaluation of disease activity.

Not yet recruiting

Conditions: Systemic lupus erythematosus (SLE),

Registration Number: CTRI/2021/06/034122

Lead Sponsor: DR Manjunath Hande

Brief Summary: SLE is a systemic autoimmune disease of unknown etiology with varied clinical and laboratory characteristics, it can potentially cause substantial physical and functional disability, ranging from a rash to renal failure or even death. There is a lack of SLE registries from INDIA, which poses as a major barrier to understand patient and disease characteristics. To predict the SLE flare, we currently have a 24 parameter SLEDAI score, but no single lab test exists to recognize the flare and increase in SLE disease activity. Several studies suggest that people with active SLE have neutrophilia and lymphopenia***.*** The presence of Anti lymphocyte antibody is important in the mechanism of lymphopenia in SLE. Platelet activation is observed in patients with SLE due to inflammatory cytokines and complement. There occurs consumption of large activated platelets in extravascular sites of inflammation. In this study we will understand the profile of SLE in patients presenting to a tertiary care hospital and we will correlate the role of NLR and MPV in identifying the SLE flare. Also, NLR and MPV are readily available even at a PHC, thus increasing the chances of identifying the SLE flare at every level of healthcare.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 123

Inclusion Criteria

Patients >18-year-old diagnosed as SLE with new ACR and EULAR criteria/ SLICC criteria.

Exclusion Criteria

Patient with sepsis/other active infections Overlap syndromes with other rheumatological diseases Acute/chronic kidney disease (other than lupus nephritis) Leukaemia, lymphoma, malignancies Vasculitis Acute MI, Acute stroke Patients on systemic steroids >5mg/day Uncontrolled diabetes HbA1c > 7%.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To have good study about the clinical characteristics of patients of SLE presenting to the hospital	At baseline
To know the immunological profile of patients of SLE	At baseline

Secondary Outcome Measures

Name	Time	Method
significant increase in neutrophil lymphocyte ratio in people with active SLE	significant reduction in mean platelet volume in patients with active SLE active SLE based on SLEDAI score

Trial Locations

Locations (1): Kasturba Hospital, Manipal
🇮🇳
Udupi, KARNATAKA, India
Kasturba Hospital, Manipal
🇮🇳Udupi, KARNATAKA, India
Dr Satinder pal singla
Principal investigator
8968259035
satimanu11@gmail.com